Last reviewed 2026-04-23 · How we verify

Triple Antigen™

Triple Antigen™ is a vaccine that stimulates immune responses against three disease antigens simultaneously to provide combined protection.

Triple Antigen™ is a vaccine that stimulates immune responses against three disease antigens simultaneously to provide combined protection. Used for Immunization against diphtheria, pertussis, and tetanus (DPT).

At a glance

Mechanism of action

Triple Antigen™ is a combination vaccine containing antigens from three infectious diseases, designed to elicit humoral and cellular immune responses against all three pathogens in a single formulation. By presenting multiple antigens, it provides simultaneous immunization and protection against three diseases, reducing the number of injections needed compared to separate vaccines.

Approved indications

• Immunization against diphtheria, pertussis, and tetanus (DPT)

Common side effects

• Local injection site reactions (pain, redness, swelling)
• Fever
• Irritability or fussiness
• Drowsiness

Key clinical trials

• A Study to Investigate LYL797 in Adults With Solid Tumors (PHASE1)
• QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy (PHASE1, PHASE2)
• Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Triple Antigen™ CI brief — competitive landscape report
• Triple Antigen™ updates RSS · CI watch RSS
• GlaxoSmithKline portfolio CI